The tyrosine kinase inhibitor (TKI) imatinib is a potent inhibitor of the PDGFR, and is used to treat gastrointestinal stromal tumors, some forms of leukemia, and myeloproliferative diseases among others. Here, PDGFRB is linked to myeloproliferative disorder.